Clinical and bacteriological evaluation of the efficacy of piperacillin in children with pneumonia

Aoki, Masato; Fukao, Toshiyuki; Kaneko, Hideo; Mizunaga, Shingo; Mitsuyama, Junichi; Sawamura, Hiromasa; Seishima, Mitsuru; Kondo, Naomi

doi:10.1007/s10156-007-0529-4

Cited by 3 publications

(2 citation statements)

References 16 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In children, the recommended doses of piperacillin and tazobactam are 50 mg/kg and 6.25 mg/kg, respectively, or 100 mg/ kg and 12.5 mg/kg, respectively, every 6 hours [17]. The combination piperacillin-tazobactam is efficacy, safe, and well tolerated in infants and children and improves the clinical and bacteriological effects [4,[6][7][8][9][10][11]. Reed et al [12] administered 600 or 900 mg/kg piperacillin daily, divided in 6 doses, to 30 children aged ≤ 12 years.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical pharmacology of piperacillin-tazobactam combination in infants and children

Pacifici¹

2019

Clin Med Invest

View full text Add to dashboard Cite

Piperacillin is a potent antibiotic and tazobactam is an inhibitor of β-lactamase. Piperacillin-tazobactam combination has a broad spectrum of activity encompassing most gram-positive, gram-negative, aerobic and anaerobic bacteria, including many producing β-lactamase organisms. The dose of piperacillin is 90 mg/kg every 6-8 hours in infants aged 1 month to 1 year. In children, the recommended doses of piperacillin and tazobactam are 50 mg/kg and 6.25 mg/kg or 100 mg/kg and 12.5 mg/kg, respectively, every 6 hours. Piperacillin and tazobactam are mainly excreted as unchanged drugs in the urine, and high biliary concentrations are achieved. The piperacillin elimination half-life is variable in neonates and ranges from 3.5 to 14 hours, whereas in infants aged between 1 and 6 months, the half-life is 47 min. The piperacillin-tazobactam combination is effective, safety, and well tolerated in infants and children. After a single intravenous infusion of 50 mg/kg piperacillin to infants and children aged 1 month to 12 years, the mean plasma concentrations of piperacillin rapidly decayed and were

show abstract

Section: Discussionmentioning

confidence: 99%

“…Aoki et al [10] prospectively evaluated the clinical and bacteriological effects of piperacillin in children with pneumonia. Twenty-eight patients (aged 6 months to 5 years) were treated with piperacillin.…”

Section: Efficacy and Safety Of Piperacillin-tazobactam In Infants And Childrenmentioning

confidence: 99%